BLUEBIRD BIO INC's ticker is BLUE and the CUSIP is 09609G100. A total of 282 filers reported holding BLUEBIRD BIO INC in Q4 2019. The put-call ratio across all filers is 0.80 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $354 | +52.6% | 56 | 0.0% | 0.00% | – |
Q2 2022 | $232 | -14.7% | 56 | 0.0% | 0.00% | – |
Q1 2022 | $272 | -51.3% | 56 | 0.0% | 0.00% | – |
Q4 2021 | $559 | -47.8% | 56 | 0.0% | 0.00% | – |
Q3 2021 | $1,070 | -78.6% | 56 | -64.1% | 0.00% | – |
Q2 2021 | $4,989 | +6.1% | 156 | 0.0% | 0.00% | – |
Q1 2021 | $4,703 | -86.5% | 156 | -80.6% | 0.00% | -100.0% |
Q4 2020 | $34,876 | -55.7% | 806 | -44.8% | 0.00% | -60.0% |
Q3 2020 | $78,767 | -12.8% | 1,460 | -1.4% | 0.01% | -16.7% |
Q2 2020 | $90,339 | +73.9% | 1,480 | +31.0% | 0.01% | +50.0% |
Q1 2020 | $51,935 | -32.7% | 1,130 | +28.4% | 0.00% | -20.0% |
Q4 2019 | $77,220 | +1301.7% | 880 | +1366.7% | 0.01% | – |
Q3 2019 | $5,509 | -27.8% | 60 | 0.0% | 0.00% | -100.0% |
Q2 2019 | $7,632 | -19.2% | 60 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $9,440 | +58.6% | 60 | 0.0% | 0.00% | 0.0% |
Q4 2018 | $5,952 | -79.3% | 60 | -69.5% | 0.00% | -66.7% |
Q3 2018 | $28,762 | +6.5% | 197 | +14.5% | 0.00% | -25.0% |
Q2 2018 | $26,995 | +50.6% | 172 | +63.8% | 0.00% | +33.3% |
Q1 2018 | $17,929 | – | 105 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANG CAPITAL MANAGEMENT LLC | 6,335,528 | $40,104,000 | 4.92% |
qPULA Trading Management LP | 14,344 | $91,000 | 0.80% |
Frazier Life Sciences Management, L.P. | 1,440,757 | $9,120,000 | 0.70% |
Ikarian Capital, LLC | 462,628 | $2,928,000 | 0.58% |
Birchview Capital, LP | 98,000 | $620,000 | 0.44% |
HealthCor Management, L.P. | 455,000 | $2,880,000 | 0.36% |
Financial Advocates Investment Management | 45,071 | $3,538,000 | 0.29% |
PDT Partners, LLC | 262,767 | $1,663,000 | 0.25% |
Monaco Asset Management SAM | 80,000 | $506,000 | 0.19% |
Summit X, LLC | 103,424 | $651,000 | 0.19% |